#### REVIEW



# Probiotics and synbiotics for preventing postoperative infectious complications in colorectal cancer patients: a systematic review and meta-analysis

Y. Chen<sup>1</sup> · A. Qi<sup>1</sup> · D. Teng<sup>1</sup> · S. Li<sup>1</sup> · Y. Yan<sup>1</sup> · S. Hu<sup>1</sup> · X. Du<sup>1</sup>

Received: 23 October 2021 / Accepted: 22 January 2022 / Published online: 29 March 2022 © Springer Nature Switzerland AG 2022

# Abstract

**Background** The health benefits of probiotics and synbiotics in healthy adults are well established, but their role in preventing infectious complications after surgery for colorectal cancer remains controversial. The aim of this meta-analysis was to assess the impact of probiotics/synbiotics on the incidence of infectious complications in patients who had surgery for colorectal cancer.

**Methods** A comprehensive literature search of all randomized control trials (RCTs) was conducted using PubMed, Embase, World Health Organization (WHO) Global Index Medicus, WHO clinical trial registry, and Clinicaltrials.gov. Inclusion criteria included RCTs comparing the use of any strain or dose of a specified probiotic/synbiotic with placebo or a "standard care" control group. The incidence of postoperative infectious complications was analyzed.

**Results** Fourteen RCTs involving 1566 patients (502 receiving probiotics, 273 receiving synbiotics, and 791 receiving placebo) were analyzed. Overall, probiotic or synbiotic administration significantly reduced the risk of developing postoperative infectious complications by 37% (relative risk (RR) = 0.63, 95% confidence interval (CI) 0.54–0.74, p < 0.001). Furthermore, when considering the six different types of postoperative infectious complications (septicemia, incision infection, central line infection, pneumonia infection, urinary infection, and incidence of diarrhea), probiotic or synbiotic administration was beneficial in reducing the incidence of each one of them. The quality of evidence was listed below: incidence of diarrhea (high), septicemia (moderate), incision infection (moderate), pneumonia infection (moderate), and central line infection (low). However, for the main outcome of infectious complications, we found evidence of possible publication bias, although estimates still showed a reduction following trim-and-fill analysis (RR=0.72, 95% CI 0.62–0.84, p < 0.001).

**Conclusions** The use of probiotic/synbiotic supplementation is associated with a significant reduction in the risk of developing postoperative infectious complications in patients who had surgery for colorectal cancer. Additional studies are needed to confirm the findings due to publication bias and low quality of evidence.

Keywords Probiotics · Synbiotics · Postoperative infectious complications · Colorectal cancer surgery

Y. Chen and A. Qi have contributed equally to this work.

X. Du duxiaohui301@sina.com

<sup>1</sup> Department of General Surgery, The First Medical Center, Chinese PLA General Hospital, Haidian, Beijing 100853, China

# Introductions

Colorectal cancer (CRC) is one of the most common cancers. It ranks third in terms of incidence and second in mortality worldwide, accounting for 1.8 million new cases and almost 900,000 deaths [1]. In the adults over 65 years of age, CRC incidence and mortality have decreased steadily in recent decades. However, in adults under 50 years of age, the incidence of CRC presents an obvious rising trend [2]. The disease burden of CRC on the whole population continues to increase. The etiology of CRC is complex, Surgery is the main treatment option at present [3]. Although surgical management has significantly improved, postoperatively a considerable number of patients still develop infectious complications, which may cause sepsis, multiple organ dysfunction, and even lead to death if not diagnosed in time [4, 5]. Postoperative infection is closely related to disorders of gut microbiota, and the occurrence and development of postoperative infection can be effectively prevented by regulating gut microbiota [6].

Probiotics are active microorganisms that are beneficial to the host by regulating the immune function of the host mucosa and the system, or by regulating the balance of intestinal flora [7]. Prebiotics are organic substances that are not digested or absorbed by the host but selectively promote the metabolism and proliferation of beneficial bacteria in the body, thus improving the health of the host [8]. When prebiotics are used in combination with probiotics, they are known as synbiotics [9]. Probiotics have been shown to play a multifaceted role in preventing gastrointestinal infections; they can promote the digestion and absorption of nutrients, improve the body's immunity, maintain the structural balance of intestinal flora, improve the body's antioxidant level, and protect the intestinal mucosal barrier [10–12]. These nutritional adjuncts have potential benefits of reducing the incidence of postoperative infection.

Many randomized controlled trials (RCTs) have reported the effect of probiotics [13–21] or synbiotics [22–25] on reducing postoperative infection complications with inconsistent results, most likely due to variations in experiment design and methodological measurements. Some recent studies have been published to demonstrate the benefits of probiotics or synbiotics; however, they did not evaluate the publication bias, risk of bias, and rate the quality of evidence [26, 27]. Therefore, an explicit systematic review and meta-analysis were needed to evaluate the effect of perioperative or postoperative probiotics/synbiotics on postoperative infectious complications in adult patients undergoing colorectal resections.

# **Materials and methods**

#### **Study selection**

All RCTs evaluating the effect of probiotics or synbiotics on preventing postoperative infection complications were searched using PubMed (1966–2021), Embase (1980–2021), and World Health Organization (WHO) Global Index Medicus. Unpublished or ongoing studies were identified by checking clinical trials registers through Clinicaltrials.gov and WHO clinical trial registry. Literature in all languages was included in the search. Meta-analyses, and systematic reviews were also hand-searched to find relevant literature that might have been missed by the initial search. Logical combinations of "probiotics," "synbiotics," "Lactobacillus", "Bifidobacterium", "infection complications", and "colorectal cancer" were used as keywords to search for relevant literatures. RCTs of any route of administration and dose were accepted, either preoperatively, postoperatively, or both. Control groups should be those that did not receive any probiotics or synbiotics. Only CRC surgery in patients > 18 years of age was included.

#### Data extraction

Articles retrieved from the searches were evaluated independently by two reviewers (Yuhui Chen and Aiying Qi) using predefined standardized data extraction forms, and then, data were evaluated by a third reviewer (Xiaohui Du) independently based on the United States National Institute of Health National Heart, Lung, and Blood Institute (NHLBI) study quality assessment tool for controlled intervention studies [28]. Clinical outcome of interest was incidence of postoperative infectious complications as defined by the trial authors. Data pertaining to patients, the kinds of probiotics or synbiotics, control groups, and methodology were abstracted (Fig. 1).

#### **Meta-analysis**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement methodology [29] was adhered to. Relative risks (RRs) with a 95% CI for postoperative infectious complications of each trial were calculated to estimate treatment effects. Meta-analysis of the pooled data was performed using the fixed-effect model or random-effects model, depending on the heterogeneity of the included studies. If clinical heterogeneity was observed, data were analyzed using a random-effect model. Heterogeneity was quantified using the Cochrane's Q statistic and  $I^2$ statistic, with the values of 25%, 50%, and 75% signifying the limits of low, moderate, and high statistical heterogeneity, respectively [30]. A funnel plot was used to explore publication bias for the studies and was further evaluated using Egger's test [31]. A two-tailed p value of < 0.05 was considered statistically significant. All statistical analyses were performed using R package *meta* (R version 4.0.1).

The risk of bias was evaluated using the Cochrane risk of bias tool. It was used to evaluate the selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. The evidence quality was evaluated using the GRADEPro based on the results of systematic evaluation. To achieve transparency and implicity, the GRADE system classifies the certainty of evidence in one of four grades: high: further research is very unlikely to



Fig. 1 PRISMA flow diagram showing the process of literature screening, study selection, and reasons for exclusion. *PRISMA* Preferred Reporting Items for Systematic Reviews and Meta-Analyses, *RCT* randomized controlled trial

change our confidence in the estimate of effect; moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low: any estimate of effect is very uncertain.

When publication bias exists in the results, the trimand-fill method was used to test whether this publication bias would affect the results of the comprehensive effect size [32]. The basic idea is to cut out the asymmetric part of the funnel plot after initial estimation, the center value of the funnel plot was estimated using the remaining symmetric part, then the cut part and corresponding missing part were patched along both sides of the center, and finally, the value of the combined effect size was estimated based on the patched funnel plot.

# Results

#### Demographic characteristics of the studies

The literature search process, shown in Fig. 1, identified 221 potential studies for fully analyses. Following application of exclusion criteria, 14 studies were identified for further quantitative meta-analyses [13–25, 33] (Fig. 1), involving a total of 1566 patients. Of 14 studies included in the final analysis, 5 studies used probiotics or synbiotics preoperatively, 8 studies used probiotics or synbiotics both preoperatively and postoperatively, and only 1 study used them postoperatively (Table 1). The probiotic strains used were *Lactobacillus acidophillus, L. casei, L. paracasei, L. bulgaricus, L. paracasei, L. plantarum, Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium longus,* 

-201
1966
ns (1
catio
mpli
on co
fectio
ve in
erati
ostop
d uo
otics
synbi
s or s
iotic
prob
se of
the u
ting 1
/alua
als ev
ol tri
contro
ized (
ndom
ll ran
of a
acteristics
Char
le 1
Tab

Table 1 Characteri	stics of all ra	indomized control trials evaluating the use of pr	cobiotics or synbic	otics on postoperative infection complications (19	66-2019)			
Study name, year	Treatment	Component	Preop /postop durations	Antibiotics prophylactic regimens	Control	Blinding	No. of ran trial partic	lomized ipants
			(days)				Treatment	Control
Liu 2011	Probiotic	L plantarum, Lacidophilus, and B longum	6/10	Preop: ceftriaxone 1 g + metronidazole 500 mg given 1 h before induction Postop: ceftriaxone 1 g + metronidazole 500 mg continued for 48 h	Placebo	Yes	50	50
Mangell 2012	Probiotic	L plantarum 299v	8/5	Preop: cefuroxime + metronidazole given at induction of anesthesia Postop: not reported	Placebo	Yes	32	32
Zhang 2012	Probiotic	B longum, Lacidophilus, and E faecalis	3/0	Preop: gentamicin 80 000U tid + metronida- zole 0.4 g tid the day before surgery; cefuro- xime sodium 3 g during surgery Postop: cefuroxime 3 g bid + nmetronidazole 1 g bid continued for 3–5 days	Placebo	Yes	30	30
Sadahiro 2014	Probiotic	Bifidobacteria	2-8/5-15	Preop: flomoxef 1 g given 1 h before inci- sion; additional flomoxef 1 g if operation time > 3 h Postop: Not reported	Placebo	No	100	95
Liu 2013	Probiotic	L plantarum, Lacidophilus, and B longum	6/10	Preop: ceftriaxone 1 g+metronidazole 500 mg given 1 h before induction Postop: ceftriaxone 1 g+metronidazole 500 mg continued for 48 h	Placebo	Yes	75	75
Liu 2015	Probiotic	L plantarum, Lacidophilus, and B longum	6/10	Preop: ceftriaxone 1 g+metronidazole 500 mg given 1 h before induction Postop: ceftriaxone 1 g+metronidazole 500 mg continued for 48 h	Placebo	Yes	66	68
Kotzampassi 2015	Probiotic	L acidophilus, L plantarum, B lactis, and S boulardii	0/14	Preop: metronidazole 500 mg tid the day before surgery; 2nd generation cefalo- sporin+metronidazole given before incision Postop: not reported	Placebo	Yes	84	80
Consoli 2016	Probiotic	Saccharomyces Boulardii	0/L	Preop: gentamicin 240 mg + metronidazole 500 mg given 30 min before surgery Postop: gentamicin 240 mg + metronidazole 500 mg tid for 24 h	Standard care	No	15	18
Tan 2016	Probiotic	L acidophilus, L casei, L lactis, B bifidum, B longum, and B infantis	0/L	Preop: cefuroxime 1.5 g + flagyl 500 mg given before surgery Postop: cefuroxime 1.5 g + flagyl 500 mg continued if indicated	Placebo	Yes	20	20
Yang 2016	Probiotic	B longum, L acidophilus and E faecalis	5/7	Preop: cefoxitin 1 dose before surgery; Postop: cefoxitin continued if needed	Placebo	Yes	30	30
Horvat 2010	Synbiotics	Mixture of 4 lactobacilli and beta-glucan, inulin, starch, pectin	3/0	Not reported	Placebo	Yes	20	20
Komatsu 2016	Synbiotics	L casei strain Shirita, B breve strain Yakult and galacto-oligosaccharides	7-11/2-7	Preop: cefotiam hydrochloride 1 g given 1 h before operation Postop: cefotiam hydro- chloride continued for 24 h	Standard care	No	168	194

Streptococcus thermophilus, Pediacoccus pentosaceus, and Leuconostoc mesenteroides. The prebiotics used were oligofructose powder, oat fiber, beta-glucan, inulin, pectin, and resistant starch. Nine studies used probiotics as the sole intervention with the remaining four studies using synbiotics instead.

# Effects of probiotics or synbiotics on postoperative infectious complications

Overall, the probiotics or synbiotics can prevent developing postoperative infectious complications as compared to the control group who received placebo or standard care (RR = 0.63, 95% CI 0.54 - 0.74, p < 0.001; Fig. 2). There was no significant heterogeneity between trials ( $I^2 = 7\%$ ). Of 14 studies included in the final analysis, 10 studies used probiotics as the sole intervention with the remaining 4 studies using synbiotics only. In the probiotic group, the incidence of postoperative infectious complications showed a significantly lower risk compared to the control group (RR = 0.65, 95% CI 0.54–0.78, p < 0.001; Fig. 2). No between-study heterogeneity was observed ( $I^2 = 0\%$ ). In the synbiotics group, meta-analysis showed no significantly lower risk of developing postoperative infectious complications compared to the control group (RR = 0.57, 95% CI 0.39-0.84, p < 0.001; Fig. 2). There is moderate heterogeneity between studies  $(I^2 = 55\%)$ . The subgroup difference between probiotics and synbiotics was not significant (p = 0.54).

# Effects of preoperative or postoperative administration of probiotics/synbiotics on postoperative infectious complications

Of the14 studies included in the final analysis, 5 studies used probiotics or synbiotics preoperatively, 8 studies used probiotics or synbiotics both preoperatively and postoperatively, and only 1 study used them postoperatively. Overall, preoperative or postoperative administration of probiotics/synbiotics was beneficial in reducing the risk of postoperative infectious complications (RR=0.63, 95% CI 0.54-0.74, p < 0.001; Fig. 3). Subgroup analysis showed that preoperative administration was beneficial in reducing the risk of developing postoperative infectious complications (RR = 0.33, 95% CI 0.17 - 0.61, p < 0.001; Fig. 3). However, the benefit of postoperative administration was not discovered (RR = 0.66, 95% CI 0.38–1.16, p = 0.15; Fig. 3). When probiotics or synbiotics were administrated both preoperatively and postoperatively, the incidence of postoperative infectious complications in the treatment group was reduced significantly (RR = 0.68, 95% CI 0.57–0.81, p < 0.001; Fig. 3). No between-study heterogeneity was observed in any subgroups  $(I^2 = 0\%; I^2 = 11\%; \text{Fig. 3})$ , and the subgroup difference was not significant (p = 0.09).

Study name, year	Treatment	Component	Preop /postop durations	Antibiotics prophylactic regimens	Control	Blinding	No. of randc trial particip	mized ants
			(days)				Treatment	Control
Flesch 2017	Synbiotics	L acidophilus, L rhamnosus,L paracasei, B lactis, and fructo-oligosaccharides	5/14	Preop: gentamicin and metronidazole 1 h before surgery Postop: not reported	Placebo	Yes	49	42
Polakowski 2019	Synbiotics	L acidophilus, L rhamnosus, L casei, B lactis, and fructoolig osaccharide	0/L	Not reported	Placebo	Yes	36	37
Preop preoperativ	e, <i>Postop</i> post	toperative						

Table 1 (continued)

**Fig. 2** Forest plot of probiotics or synbiotics from randomized controlled trials demonstrating the effect on risk ratio for postoperative infectious complications

Study	Events	Treat Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight
Type = Probiotics								
Liu 2011	7	50	15	50		0.47	[0.21; 1.05]	6.0%
Mangell 2012	4	32	6	32		0.67	[0.21; 2.14]	2.4%
Zhang 2012	3	30	10	30		0.30	[0.09; 0.98]	4.0%
Sadahiro 2014	24	100	24	95	÷	0.95	[0.58; 1.55]	9.8%
Liu 2013	41	75	55	75	100 H	0.75	[0.58; 0.95]	22.0%
Liu 2015	15	66	26	68		0.59	[0.35; 1.02]	10.2%
Kotzampassi 2015	16	84	23	80		0.66	[0.38; 1.16]	9.4%
Consoli 2016	2	15	7	18		0.34	[0.08; 1.41]	2.5%
Tan 2016	4	20	8	20		0.50	[0.18; 1.40]	3.2%
Yang 2016	9	30	17	30		0.53	[0.28; 0.99]	6.8%
Fixed effect model		502		498	\$	0.65	[0.54; 0.78]	76.4%
Heterogeneity: $I^2 = 0\%$	$t_{0}, \tau^{2} = 0, \mu$	0 = 0.6	1					
Type = Synbiotics								
Horvat 2010	0	20	1	20		0.33	[0.01; 7.71]	0.6%
Komatsu 2016	29	168	44	194		0.76	[0.50; 1.16]	16.3%
Flesch 2017	1	49	9	42		0.10	[0.01; 0.72]	3.9%
Polakowski 2019	1	36	7	37		0.15	[0.02; 1.13]	2.8%
Fixed effect model		273		293	$\diamond$	0.57	[0.39; 0.84]	23.6%
Heterogeneity: $I^2 = 55^{\circ}$	$\%, \tau^2 = 0.$	.8640, p	0.08					
Fixed effect model	2	775		791	Å	0.63	[0.54; 0.74]	100.0%
Heterogeneity: $I^2 = 7\%$	$\tau_{0}, \tau_{1}^{2} = 0.0$	079, p	= 0.38		1 1 1 1 1			
Test for subgroup diffe	erences: $\chi$	1 = 0.3	8, df = 1 (	p = 0.54	i) 0.1 0.51 2 10			

**Fig. 3** Forest plot of preoperative or postoperative administration of probiotics/synbiotics from randomized controlled trials demonstrating the effect on risk ratio for postoperative infectious complications

Study	Events	Treat Total	Co Events	ntrol Fotal	Risk Ratio	RR	95%-CI	Weight
Intervention = Both								
Liu 2011	7	50	15	50		0.47	[0.21; 1.05]	6.0%
Mangell 2012	4	32	6	32		0.67	[0.21; 2.14]	2.4%
Sadahiro 2014	24	100	24	95	<del>: •</del>	0.95	[0.58; 1.55]	9.8%
Liu 2013	41	75	55	75		0.75	[0.58; 0.95]	22.0%
Liu 2015	15	66	26	68		0.59	[0.35; 1.02]	10.2%
Yang 2016	9	30	17	30		0.53	[0.28; 0.99]	6.8%
Komatsu 2016	29	168	44	194		0.76	[0.50; 1.16]	16.3%
Flesch 2017	1	49	9	42 -		0.10	[0.01; 0.72]	3.9%
Fixed effect model		570		586	\$	0.68	[0.57; 0.81]	77.5%
Heterogeneity: $I^2 = 119$	$\%, \tau^2 = 0.$	0095, p	0.34					
Intervention = Pre-	operatio	n						
Zhang 2012	3	30	10	30		0.30	[0.09; 0.98]	4.0%
Consoli 2016	2	15	7	18		0.34	[0.08; 1.41]	2.5%
Tan 2016	4	20	8	20		0.50	[0.18; 1.40]	3.2%
Horvat 2010	0	20	1	20		0.33	[0.01; 7.71]	0.6%
Polakowski 2019	1	36	7	37		0.15	[0.02; 1.13]	2.8%
Fixed effect model		121		125	$\sim$	0.33	[0.17; 0.61]	13.1%
Heterogeneity: $I^2 = 0\%$	$, \tau^2 = 0, \mu$	o = 0.87	7					
Intervention = Post	-operati	on						
Kotzampassi 2015	16	84	23	80		0.66	[0.38; 1.16]	9.4%
Fixed effect model		84		80	$\diamond$	0.66	[0.38; 1.16]	9.4%
Heterogeneity: not app	licable							
Fixed effect model	2 0 0	775		791	↓ ↓	0.63	[0.54; 0.74]	100.0%
Heterogeneity: I <sup>2</sup> = 7% Test for subgroup diffe	, τ <sup>-</sup> = 0.0 rences: χ	$\frac{079}{2} = 4.78$	= 0.38 8, df = 2 (p	= 0.09	) 0.1 0.51 2 10			

# Effects of probiotics or synbiotics on different types of postoperative infectious complications

The effects of probiotics or synbiotics on different types of postoperative infectious complications were also explored (Fig. 4). Six types of postoperative infectious complications were reported in the meta-analyses: septicemia, incision infection, central line infection, pneumonia infection, urinary infection, and incidence of diarrhea. Results showed that the use of probiotics/synbiotics was associated with a significant decrease in the 6 types of postoperative infectious complications (septicemia: RR = 0.65, 95% CI 0.55–0.78, Fig. 4 Forest plot of probiotics or synbiotics from randomized controlled trials demonstrating the effect on risk ratio for different types of postoperative infectious complications

A. 5	epticemia							
	Study	Events	Treat Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI Weight
	Mangell 2012	4	32	6	32		0.67	[0 21 2 14] 4 5%
	Zhang 2012	1	30	å	30		0.13	[0.02: 0.94] 6.1%
	Lin 2013	41	75	55	75	in the second se	0.75	[0.58: 0.05] 41.6%
	Liu 2013	41	15	55	15	20	0.75	[0.58, 0.95] 41.6%
	Liu 2015	39	66	60	68	ingel .	0.67	[0.54; 0.83] 44.7%
	Kotzampassi 2015	1	84	4	80		0.24	[0.03; 2.08] 3.1%
	Fixed effect model Heterogeneity: $I^2 = 12$	2%, $\tau^2 = 0$ .	<b>287</b> 0068, µ	0 = 0.34	285	¢	0.65	[0.55; 0.78] 100.0%
D 7						0.1 0.512 10		
B. Ii	icision infection							
	Study	Events	Treat Total	Con Events	ntrol Fotal	Risk Ratio	RR	95%-CI Weight
	Liu 2011	3	50	5	50		0.60	0 15 2 381 5 5%
	Sadabira 2014	6	00	17	05		0.00	[0.14: 0.92] 10.0%
	Sadariiro 2014	0	99	17	95		0.34	[0.14, 0.82] 19.2%
	Liu 2015	6	66	8	68		0.77	[0.28; 2.11] 8.7%
	Kotzampassi 2015	6	84	16	80		0.36	[0.15; 0.87] 18.1%
	Tan 2016	1	20	2	20 -	•;	0.50	[0.05; 5.08] 2.2%
	Yang 2016	1	30	1	30		1.00 [	0.07; 15.26] 1.1%
	Komatsu 2016	29	168	44	194		0.76	[0.50; 1.16] 45.1%
	Fixed effect model Heterogeneity: $I^2 = 0$	%, τ <sup>2</sup> = 0, μ	<b>517</b> 0 = 0.60	)	537		0.60	0.44; 0.81] 100.0%
						0.1 0.5 1 2 10		
C. C	central line infection							
	Study	Evente	Treat	Co	ntrol	Pick Potio	DD	95% CI Weight
	Study	Events	Total	Events	lotal	RISK RATIO	RR	95%-CI weight
	Liu 2011	1	50	7	50 -		0.14	[0.02: 1.12] 27.0%
	Liu 2013	4	75	12	75		0.33	[0 11: 0 99] 46.3%
	Lin 2015	7	66	6	60		1.00	[0.11, 0.00] 40.070
	Liu 2015	1	00	0	68	1	1.20	[0.43; 3.39] 22.8%
	Tan 2016	1	20	1	20		1.00	[0.07; 14.90] 3.9%
	Fixed effect model		211		213	$\diamond$	0.51	[0.27; 0.96] 100.0%
		2 0						
	Heterogeneity: $I^- = 39$	$\frac{10}{10} \tau^{-} = 0$	3658 r	= 0.18				
	Heterogeneity: $I^{-} = 39$	$9\%, \tau^{-} = 0.$	3658, p	0 = 0.18				
	Heterogeneity: /~ = 39	<b>3%</b> , τ <sup>-</sup> = 0.	3658, p	0 = 0.18		0.1 0.5 1 2 10		
DI	Heterogeneity: /~ = 39	9%, τ <sup>-</sup> = 0.	3658, p	9 = 0.18		0.1 0.5 1 2 10		
D. F	Heterogeneity: /~ = 39	3%, τ <sup>-</sup> = 0.	3658, p	9 = 0.18		0.1 0.5 1 2 10		
D. F	Preumonia infection	<b>3</b> ‰, τ <sup>-</sup> = 0.	3658, p Treat	o = 0.18 Cc	ontrol	0.1 0.5 1 2 10		
D. F	Heterogeneity: /~ = 38 Pneumonia infection Study	First First Strength First Stren	3658, p Treat Total	e = 0.18 Co Events	ontrol Total	0.1 0.5 1 2 10	RR	95%-Cl Weight
D. F	Heterogeneity: /~ = 38 Pneumonia infection Study	9%, τ <sup>-</sup> = 0. Events	3658, p Treat Total	e = 0.18 Co Events	ontrol Total	0.1 0.5 1 2 10	RR	95%-CI Weight
D. F	Preumonia infection Study Liu 2011	9%, τ <sup>-</sup> = 0. Events	Treat Total	e = 0.18 Co Events	ontrol Total	0.1 0.5 1 2 10	<b>RR</b>	95%-CI Weight
D. F	Preumonia infection Study Liu 2011 Liu 2013	9%, τ <sup>-</sup> = 0. Events 2	3658, p Treat Total 50	cc Events 5	ontrol Total	0.1 0.5 1 2 10	<b>RR</b> 0.40	95%-CI Weight
D. F	Areumonia infection Study Liu 2011 Liu 2015	9%, τ <sup>-</sup> = 0. Events 2 3	3658, p Treat Total 50 75	cc Events 5 10	ontrol Total	0.1 0.5 1 2 10	<b>RR</b> 0.40 0.30	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6%
D. F	Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Concepts	2%, τ <sup>-</sup> = 0. Events 2 3	3658, p Treat Total 50 75 66	cc Events 5 10 8	ontrol Total 50 75 68	0.1 0.5 1 2 10	<b>RR</b> 0.40 0.30 0.77	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3%
D. F	Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016	9%, τ <sup>-</sup> = 0. <b>Events</b> 2 3 6 1	3658, p Treat Total 50 75 66 20	cc Events 5 10 8 1	50 75 68 20	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5%
D. F	Anteriogeneity: /* = 38 Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016	2%, τ <sup>-</sup> = 0. <b>Events</b> 2 3 6 1 3	3658, p Treat Total 50 75 66 20 30	Cc Events 5 10 8 1 5	50 75 68 20 30	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60	<b>95%-Cl Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3%
D. F	Anterogeneity: /* = 38 Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016	9%, τ <sup>-</sup> = 0. Events 2 3 6 1 3 3 3	3658, p Treat Total 50 75 66 20 30	Cc Events 5 10 8 1 5	50 75 68 20 30	0.1 0.51 2 10	RR 0.40 0.30 0.77 - 1.00 0.60	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3%
D. F	Anterogeneity: /* = 38 Anterna infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode	Events 2 3 6 1 3	3658, p Treat Total 50 75 66 20 30 241	0 = 0.18 Cc Events 5 10 8 1 5	50 75 68 20 30 <b>243</b>	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 0.52	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D. F	Atterogeneity: /* = 38 Aneumonia infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: / <sup>2</sup> = 0	<b>Events</b> 2 3 6 1 3 $F^2 = 0, T^2 = 0, $	Treat Total 50 75 66 20 30 <b>241</b> p = 0.7	cc Events 5 10 8 1 5	50 75 68 20 30 <b>243</b>	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 0.52	<b>95%-Cl Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D. F	Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: J <sup>2</sup> = 0	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ ,	Treat Total 50 75 60 30 <b>241</b> <i>p</i> = 0.7	0 = 0.18 Events 5 10 8 1 5 9	50 75 68 20 30 <b>243</b>	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b>	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D.F	Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: I <sup>2</sup> = 0 Irinary infection	Events 2 3 6 1 3 $W, \tau^2 = 0, -$	Treat Total 50 75 66 20 30 <b>241</b> <i>p</i> = 0.7	0 = 0.18 Cc Events 5 10 8 1 5 9	50 75 68 20 30 <b>243</b>	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b>	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D. F E. U	Anterogeneity: /* = 38 Aneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: /² = 0 Vrinary infection	Wey τ <sup>2</sup> = 0. Events 2 3 6 1 3 8 1 %, τ <sup>2</sup> = 0,	3658, p Treat Total 50 75 66 20 30 20 30 241 p = 0.7	0 = 0.18 Cc Events 5 10 8 1 5 9	50 75 68 20 30 <b>243</b>	0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 0.52	<b>95%-Cl Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D. F E. U	Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $I^2 = 0$ Vrinary infection	Frequencies (1) - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	3658, p Treat Total 50 75 66 20 30 241 p = 0.7 Treat	0 = 0.18 Co Events 5 10 8 1 5 9 9	ontrol Total 50 75 68 20 30 243 243	0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52	<b>95%-CI Weight</b> [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% <b>[0.29; 0.95] 100.0%</b>
D. F E. U	Atterogeneity: /* = 38 Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: /² = 0 Prinary infection Study	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events	3658, ρ Treat Total 50 75 66 20 30 241 ρ = 0.7 Treat Treat Total	cc Events 5 10 8 1 5 9 Co Events	ontrol Total 50 75 68 20 30 243 243	0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight
D. F E. U	Anteriogeneity: /* = 38 Aneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: /² = 0 Jrinary infection Study	Events 2 3 6 1 3 W, $\tau^2 = 0$ , Events	3658, p Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total	Co Events 5 10 8 1 5 9 Co Events	ontrol Total 50 75 68 20 30 243 243 ntrol Total	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight
D. F	Heterogeneity: $r^2 = 38$ Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events	Treat Total 50 75 66 20 30 241 <i>p</i> = 0.7 Treat Total	• = 0.18 Co Events 5 10 8 1 5 9 Co Events 6	ontrol Total 50 75 68 20 30 <b>243</b> ntrol Total	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02: 1.33] 17.7%
D. F	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2011 Liu 2012	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events 1 2 3 1 3 1 1 2 3 1 3 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 0 241 50 75	Co Events 5 10 8 1 5 9 Co Events	ontrol Total 50 75 68 20 30 243 243 ntrol Total 50 7	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7%
D. F	Heterogeneity: $r^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2013	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events 1 3	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 50 75	• = 0.18 Cc Events 5 10 8 1 5 9 Co Events 6 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 243 243 ntrol Total 50 75	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10	RR 0.40 0.30 0.77 1.00 0.60 <b>0.52</b> RR 0.17 0.30	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4%
D. F	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 1 3 1 1 3 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 60 20 30 241 50 75 50 75	• = 0.18 Cc Events 5 10 8 1 5 9 Co Events 6 10 9	ontrol Total 50 75 68 20 30 243 243 ntrol Total 50 75 68	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b> RR 0.17 0.30 0.11	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.01; 0.88] 26.1%
D. F	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015	Final equation $r = 0$ , $r = 0$ , Events 2 3 6 1 3 1 $\%$ , $r^2 = 0$ , Events 1 3 1 4	Treat Total 50 75 60 20 30 241 Treat Total 50 75 60 75 60 84	• = 0.18 Events 5 10 8 10 8 10 5 9 Events 6 10 9 6 10 9 6	ontrol Total 50 75 68 20 30 <b>243</b> <b>243</b> ntrol Total 50 75 68 80	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.01; 0.88] 26.1% [0.19; 2.17] 18.1%
D. F	Heterogeneity: $r^2 = 38$ Preumonia infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016	Final equation $r_{1}^{2}$ , $r_{2}^{2} = 0$ , Events Events 1 3 1 4 1	Treat Total 50 75 66 20 30 241 75 66 50 75 66 84 40 75 66 84 10	• = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 <b>243</b> <b>243</b> <b>11</b>	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.30 0.11 1.10	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.08; 15.36] 2.8%
D. F	Preterogeneity: $r^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016	Final equation $r_{1}^{2}$ , $r_{2}^{2} = 0$ , Events Events 1 3 1 4 2 3 1 3 1 4 1 2 3 1 4 1 2 3 1 3 1 4 1 2 3 1 3 1 4 1 2 3 1 3 1 3 1 4 1 3 1 4 1 3 1 4 1 3 1 4 1 3 1 4 1 3 1 4 1 3 1 4 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 500 75 66 20 30 <b>241</b> p = 0.7 Treat Total 50 75 66 84 100 30	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 10 8 1 5 9	ontrol Total 50 75 68 20 30 <b>243</b> <b>243</b> 50 75 68 80 11 30	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.04; 15.36] 2.8% [0.15; 5.64] 5.9%
D. F	Heterogeneity: $r^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016	$r^{\infty}, \tau^{2} = 0.$ Events 2 3 6 1 3 8 ( $r^{2} = 0,$ 5 Events 1 3 1 4 4 1 2	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 20 30 241 75 66 84 10 30 75 66 66 20 30 241 Total	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 9 6 10 2	ontrol Total 50 75 68 20 30 <b>243</b> <b>243</b> <b>ntrol</b> Total 50 75 68 80 11 30	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b> RR 0.17 0.30 0.11 0.63 1.10 1.00	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.15] 28.64 [0.15; 6.64] 5.9%
D. F	Heterogeneity: $r^2 = 38$ Preumonia infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Eixed effect model	$r^{\infty}$ , $r^{2} = 0$ . Events 2 3 6 1 3 1 %, $r^{2} = 0$ , Events 1 3 1 4 1 2 1 3 1 2 1 3 1 2 1 3 1 2 3 1 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 1 3 1 3 1 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 200 30 2411 p = 0.7 Treat Total 50 75 66 84 10 30 315	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 6 10 9 Co Events 2 Co Co Co Co Co Co Co Co Co Co	ontrol Total 50 30 243 ntrol Total 50 75 68 80 11 30	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b> RR 0.17 0.30 0.11 0.63 1.10 1.00	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.11; 0.88] 26.1% [0.15] 2.17] 18.1% [0.08; 15.36] 2.8% [0.15; 6.64] 5.9% [0.142: 0.67] 100.0%
D. F	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model	Events 2 3 6 1 3 W, $\tau^2 = 0$ , Events 1 3 4 1 2 1 4 1 2 1 2 1 3 1 2 3 1 3 1 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 20 30 <b>241</b> <i>p</i> = 0.7 <b>Treat</b> <b>Total</b> 50 75 66 84 10 30 315	e = 0.18 Cc Events 5 10 8 10 8 10 5 9 Co Events 6 10 9 Co Events 10 8 1 5 9	ntrol Total 50 75 68 20 30 <b>243</b> <b>243</b> <b>11</b> 30 314	0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.08; 15.36] 2.8% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F	Heterogeneity: $l^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Jrinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 Treat Total 50 75 66 84 10 30 <b>315</b> p = 0.44	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 9 6 10 2 3	ntrol 50 75 68 20 30 243 ntrol 50 75 68 80 75 68 80 11 30 314	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.33 0.11 0.63 1.10 1.00 0.35	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.19; 2.17] 18.1% [0.08; 15.36] 2.8% [0.15; 6.64] 5.9%
D. F	Heterogeneity: $l^2 = 38$ Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $l^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Kotzampassi 2015 Kotzampassi 2016 Fixed effect model Heterogeneity: $l^2 = 0$	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 0 30 241 75 66 84 10 30 55 56 66 84 10 30 55 56 50 55 56 50 55 56 50 55 50 50 55 50 50 50 50 50 50 50 50	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 3	ntrol 50 75 68 20 30 243 ntrol Total 50 75 68 80 0 11 30 314	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b> RR 0.17 0.30 0.11 0.63 1.10 1.00 <b>0.35</b>	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.10; 0.88] 26.1% [0.11; 0.88] 26.1% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F Е. U	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $r^2 = 0$	Final sector $r = 0, r^{2} = 0, $	Treat Total 50 75 66 20 30 241 Treat Total 50 75 66 84 10 30 315 2 50 75 50 75 50 75 50 75 50 75 50 75 50 30 30 241 75 75 20 30 30 241 75 75 75 75 75 75 75 75 75 75 75 75 75	• = 0.18 Cc Events 5 10 8 10 8 9 Co Events 6 10 9 Co Events 3	ntrol 50 75 68 20 20 20 20 20 20 20 20 20 20 20 20 20	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio Risk Ratio 0.1 0.5 1 2 10	RR 0.40 0.30 0.77 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.08; 15.36] 2.8% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F E. U	Heterogeneity: $l^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $l^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Piarrhoea incidence	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 315 50 75 56 66 84 10 30 30 50 75 50 75 86 60 20 30 30 50 30 75 86 60 30 30 75 86 80 80 80 80 80 80 80 80 80 80 80 80 80	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 9 8 2 8 6 10 2 8 6 10 9 6 10 8 10 10 8 10 8 10 8 10 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 10 10 10 10 10 10 10 10 10	ntrol 50 75 68 20 30 243 ntrol Total 50 75 68 80 11 30 314	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.33 1.10 1.00 0.35	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.10; 0.88] 26.1% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F E. U F. D	Heterogeneity: $l^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Pixet offect model Heterogeneity: $l^2 = 0$	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events 1 3 1 4 1 2 1 %, $\tau^2 = 0$ , Events	Treat Total 50 75 66 20 0 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 315 p = 0.4	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 3 Co Events Co Co Events Co Events Co Co Events Co Co Events Co Co Co Co Co Co Co Co Co Co	ontrol Total 50 75 68 20 30 243 243 243 75 68 80 75 68 80 11 30 314	0.1 0.51 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.10; 0.88] 26.1% [0.19; 2.17] 18.1% [0.08; 15.5] 2.8% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F E. U F. D	Heterogeneity: $r^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $r^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $r^2 = 0$ Piarrhoea incidence Study	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 <b>241</b> 75 66 20 30 <b>241</b> 75 66 84 10 30 <b>315</b> 50 75 56 66 84 10 30 <b>315</b> 75 75 75 75 75 75 75 75 75 75 75 75 75	2 = 0.18 Co Events 5 10 8 10 8 9 Co Events 6 10 9 6 10 9 6 10 2 3 Co Events Co Co Events Co Events Co Events Co Co Co Events Co Co Co Co Co Co Co Co Co Co	ontrol Total 50 75 68 20 20 20 20 20 20 20 20 20 20 20 30 243 50 75 68 80 11 30 314 50 75 50 75 50 75 75 88 20 20 20 20 20 20 20 20 20 20 20 20 20	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35 RR	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.19; 2.17] 18.1% [0.19; 6.64] 5.9% [0.19; 0.67] 100.0%
D. F E. U F. D	Heterogeneity: $l^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Jrinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Diarrhoea incidence Study	Events 2 3 6 1 3 1 %, $\tau^2 = 0$ , Events 1 3 1 4 1 2 1 3 1 4 5 2 3 6 1 3 1 2 3 6 6 1 3 1 3 1 2 3 6 6 6 1 3 1 3 1 2 3 6 1 3 1 3 1 5 1 2 1 3 1 3 1 5 1 1 3 1 1 3 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 20 30 241 Treat Total 50 75 66 84 10 30 <b>315</b> p = 0.44 Treat Total	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 9 6 10 2 8 Co Events 6 10 8 1 5 5 9 Co Events 6 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 10 9 8 10 8 10 8 10 8 10 8 10 8 10 8 10 9 8 10 8 10 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 9 8 10 9 8 10 9 8 10 9 8 10 9 8 10 8 10 9 8 10 8 10 9 8 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 243 243 243 75 68 80 75 68 80 11 30 314 30	0.1 0.51 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 1.00 0.35 RR	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.19; 2.17] 18.1% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight
D. F E. U F. D	Heterogeneity: $l^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Jrinary infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Diarrhoea incidence Study Liu 2011	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 0 30 241 p = 0.7 Treat Total 50 75 66 84 40 30 30 50 50 50 50 50 50 50 50 50 50 50 50 50	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 3 Co Events 1 2 3 Co Events 1 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 10 8 10 8 10 8 10 10 8 10 10 8 10 10 10 9 8 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 <b>243</b> <b>243</b> <b>ntrol</b> 50 75 68 80 0 11 30 <b>314</b> <b>ontrol</b> 314	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 <b>0.52</b> RR 0.17 0.30 0.11 0.63 1.10 <b>0.35</b> RR 0.53	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.01; 0.88] 26.1% [0.19; 2.17] 18.1% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9%
D. F E. U F. D	Heterogeneity: $l^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect mode Heterogeneity: $l^2 = 0$ Prinary infection Study Liu 2011 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Piarrhoea incidence Study Liu 2011 Liu 2013	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 30 <b>315</b> p = 0.4 Treat Total 50 75 75 66 84 10 30 30 50 75 75 66 84 10 30 30 75 75 75 86 86 84 10 30 75 75 75 86 86 80 75 75 75 86 80 75 75 86 80 75 75 86 80 75 75 86 80 75 75 80 80 75 75 80 80 75 75 80 80 75 75 80 80 75 75 80 80 75 75 75 80 80 75 75 75 80 75 75 75 75 75 75 75 75 75 75 75 75 75	2 = 0.18 Cc Events 5 10 8 1 5 9 Co Events 6 10 9 6 12 3 Cc Events 1 2 3 Cc Events 1 1 5 1 1 1 1 1 5 1 1 1 1 1 1 5 1 1 1 1 5 1 1 1 1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1	ntrol 50 75 68 20 30 243 ntrol Total 50 75 68 80 11 30 314 50 75 75 75 75 75 75 75 75 75 75	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 0.35 0.53 0.50	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.15; 1.05] 29.4% [0.15; 6.64] 5.9% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.96] 25.7%
D. F E. U F. D	Heterogeneity: $I^2 = 38$ Preumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $I^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Fixed effect model Heterogeneity: $I^2 = 0$ Prinary infection Study Liu 2011 Liu 2015 Fixed effect model Heterogeneity: $I^2 = 0$ Prinary 2016	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 75 66 84 40 30 75 66 84 10 30 315 50 75 66 84 10 30 50 75 66 84 10 30 50 75 66 84 10 10 10 10 10 10 10 10 10 10 10 10 10	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 6 10 9 Co Events 10 8 1 5 9 Co Events 10 8 1 5 9 Co Events 10 8 1 5 9 Co Events 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 9 8 10 8 10 8 10 9 8 10 8 10 8 10 9 8 10 8 10 8 10 9 8 10 8 10 8 10 9 8 10 8 10 9 8 10 10 9 8 10 10 9 8 10 10 9 8 10 10 9 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 243 243 antrol Total 50 75 68 80 11 30 314 50 75 68 80 11 30 314	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.30 0.11 0.35 RR 0.53 0.50 0.53	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.08; 15.3] 2.8% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.96] 25.7% [0.32; 0.88] 35.7%
D. F E. U F. E	Heterogeneity: $I^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $I^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Yang 2016 Fixed effect model Heterogeneity: $I^2 = 0$ Piarrhoea incidence Study Liu 2011 Liu 2011 Liu 2013 Liu 2016 Yang 2016	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 <b>315</b> 50 75 66 84 10 30 <b>315</b> 75 66 84 10 30 50 75 66 63 75 75 66 66 75 75 75 75 75 75 75 75 75 75 75 75 75	2 = 0.18 Cc Events 5 10 8 10 8 9 Co Events 6 10 9 Co Events 6 10 9 Co Events 10 8 10 10 8 10 8 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 243 0 243 243 50 75 68 80 11 30 314 50 75 68 80 11 30 314	0.1 0.51 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio 0.1 0.51 2 10 Risk Ratio	RR 0.40 0.30 0.77 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35 RR 0.53 0.50 0.53	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.01; 0.88] 26.1% [0.19; 0.67] 100.0% 95%-Cl Weight [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.96] 25.7% [0.32; 0.88] 35.7% [0.32; 0.88] 35.7%
D. F E. U F. E	Heterogeneity: $l^2 = 38$ Preturnonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect mode Heterogeneity: $l^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Piarrhoea incidence Study Liu 2011 Liu 2013 Liu 2013 Liu 2013 Liu 2015 Yang 2016	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 <b>315</b> 50 75 66 84 10 30 <b>315</b> Treat Total 50 75 66 84 10 30 50 75 66 84 10 30 50 75 50 86 84 10 30 50 75 50 86 86 84 10 50 75 50 86 86 80 75 50 80 80 80 75 80 80 80 80 80 80 80 80 80 80 80 80 80	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 6 10 9 6 10 9 6 10 2 3 Co Events 10 8 1 5 9 Co Events 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 10 8 10 8 10 8 10 9 8 10 8 10 9 8 10 10 9 8 10 10 10 9 8 10 10 9 8 10 10 9 8 10 10 9 10 10 10 9 8 10 10 10 9 8 10 10 10 9 8 10 10 9 10 10 10 9 10 10 10 10 10 9 10 10 10 10 10 10 10 10 10 10	ntrol 50 75 68 20 30 243 ntrol Total 50 75 68 8 0 11 30 314 50 75 68 30 314 50 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 30 75 68 8 8 8 8 8 8 8 8 8 8 8 8 8	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.53 0.51 0.35 0.53 0.53 0.53 0.53	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.19; 2.17] 18.1% [0.15; 6.64] 5.9% [0.15; 6.64] 5.9% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.96] 25.7% [0.25; 0.99] 18.7%
D. F E. U F. D	Heterogeneity: $l^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Jrinary infection Study Liu 2011 Liu 2013 Liu 2013 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Diarrhoea incidence Study Liu 2011 Liu 2013 Liu 2016 Fixed effect model Heterogeneity: $l^2 = 0$ Diarrhoea incidence Study Liu 2011 Liu 2013 Liu 2016 Fixed effect model Heterogeneity: $l^2 = 0$	Final equation (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 <b>315</b> 50 75 56 66 84 10 30 <b>315</b> 75 56 66 84 10 30 50 75 56 66 84 10 30 50 75 56 66 84 10 30 50 75 56 66 84 10 30 50 75 56 66 84 75 50 75 56 84 75 50 75 56 86 84 75 75 75 75 86 86 84 75 75 75 86 86 80 75 75 75 75 75 75 75 75 75 75 75 75 75	2 = 0.18 Co Events 5 10 8 1 5 9 Co Events 6 10 9 Co Events 10 8 1 5 9 Co Events 10 8 1 5 9 Co Events 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 1 5 10 8 10 8 1 5 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 8 10 10 8 10 10 9 6 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 243 243 75 68 80 0 75 68 80 0 11 30 314 50 75 68 80 0 75 68 80 0 75 68 80 11 30 243 30 243 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 - 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35 RR 0.53 0.50 0.53	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.09; 1.05] 29.4% [0.01; 0.88] 26.1% [0.15; 6.64] 5.9% [0.15; 6.64] 5.9% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.88] 35.7% [0.25; 0.99] 18.7%
D. F E. U F. D	Heterogeneity: $I^2 = 38$ Pneumonia infection Study Liu 2011 Liu 2013 Liu 2015 Tan 2016 Yang 2016 Fixed effect model Heterogeneity: $I^2 = 0$ Prinary infection Study Liu 2011 Liu 2013 Liu 2015 Kotzampassi 2015 Consoli 2016 Fixed effect model Heterogeneity: $I^2 = 0^2$ Piarrhoea incidence Study Liu 2011 Liu 2011 Liu 2015 Fixed effect model Heterogeneity: $I^2 = 0^2$ Piarrhoea incidence Study Liu 2011 Liu 2015 Yang 2016 Fixed effect model Heterogeneity: $I^2 = 0^2$	Final equation $t = 0$ , $t^2 = 0$ , Events Events 1 3 1 %, $t^2 = 0$ , Events 1 3 4 1 2 1 8, $t^2 = 0$ , 1 2 1 3 1 4 1 2 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 2 1 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 3 1 4 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 2 1 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1	Treat Total 50 75 66 20 30 241 p = 0.7 Treat Total 50 75 66 84 10 30 <b>315</b> p = 0.4 Treat Total 50 75 66 84 10 30 <b>315</b> 50 75 66 84 10 30 <b>315</b> 50 75 66 84 10 30 75 50 75 66 84 10 30 75 50 75 66 84 10 30 75 50 75 75 66 84 10 75 75 66 84 10 75 75 66 84 10 75 75 75 75 75 86 80 75 75 75 75 75 75 75 75 75 75 75 75 75	2 = 0.18 Cc Events 5 10 8 10 8 9 Co Events 6 10 9 6 10 9 6 10 2 3 Cc Events 10 8 10 9 8 10 8 10 8 10 8 10 8 10 9 8 10 10 8 10 8 10 10 10 10 10 10 10 10 10 10	ontrol Total 50 75 68 20 30 243 243 50 75 68 80 11 30 314 50 75 68 80 11 30 314 50 75 68 80 11 30 314 20 20 20 20 20 20 20 20 20 20 20 20 20	0.1 0.5 1 2 10 Risk Ratio 0.1 0.5 1 2 10 Risk Ratio	RR 0.40 0.30 0.77 1.00 0.60 0.52 RR 0.17 0.30 0.11 0.63 1.10 1.00 0.35 RR 0.53 0.50 0.53 0.50 0.53 0.50	95%-Cl Weight [0.08; 1.97] 17.3% [0.09; 1.05] 34.6% [0.28; 2.11] 27.3% [0.07; 14.90] 3.5% [0.16; 2.29] 17.3% [0.29; 0.95] 100.0% 95%-Cl Weight [0.02; 1.33] 17.7% [0.9; 1.05] 29.4% [0.10; 1.33] 17.7% [0.9; 1.05] 29.4% [0.10; 1.33] 17.7% [0.9; 1.05] 29.4% [0.10; 1.33] 17.7% [0.19; 1.05] 29.4% [0.19; 1.05] 29.4% [0.19; 0.67] 100.0% 95%-Cl Weight [0.26; 1.07] 19.9% [0.26; 0.96] 25.7% [0.32; 0.88] 35.7% [0.25; 0.99] 18.7% [0.38; 0.70] 100.0%

0.5

1

2

Table 2 Probic	otics/synbiotics	compared to p	placebo in colore	ectal cancer pa	tients with dif.	ferent types of I	postoperative in	ifectious compli	cations			
Certainty asses	sment						No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other consid- erations	Treatment	Control	Relative (95% CI)	Absolute (95% CI)		
Septicemia 5	Randomized trials	Not serious	Not serious	Not serious	Serious	None	86/287 (30.0%)	133/285 (46.7%)	<b>RR 0.65</b> (0.55–0.78)	<b>163 fewer</b> <b>per 1000</b> (from 210 to	⊕⊕⊕() moderate	Important
Incision infecti 7	ion Randomized trials	Serious	Not serious	Not serious	Not serious	None	52/517 (10.1%)	93/537 (17.3%)	<b>RR 0.60</b> (0.44–0.81)	103 TEWET) 69 fewer per 1000 (from 97 to	⊕⊕⊕() moderate	Important
Central line inf 4	fection Randomized trials	Not serious	Serious	Not serious	Serious	None	13/211 (6.2%)	26/213 (12.2%)	<b>RR 0.51</b> (0.27–0.96)	33 fewer) 60 fewer per 1000 (from 89 to 5	⊕⊕ low	Important
Pneumonia inf 5	èction Randomized trials	Not serious	Not serious	Not serious	Serious	None	15/241 (6.2%)	29/243 (11.9%)	<b>RR 0.52</b> (0.29–0.95)	fewer) 57 fewer per 1000 (from 85 to 6	⊕⊕⊕() moderate	Important
Urinary infecti 6	on Randomized trials	Not serious	Not serious	Not serious	Serious	None	12/315 (3.8%)	34/314 (10.8%)	<b>RR 0.35</b> (0.19–0.67)	fewer) 70 fewer per 1000 (from 88 to	⊕⊕⊕() moderate	Important
Diarrheal incid 4	lence Randomized trials	Not serious	Not serious	Not serious	Not serious	None	44/221 (19.9%)	86/223 (38.6%)	<b>RR 0.52</b> (0.38 to 0.70)	36 fewer) 185 fewer per 1000 (from 239 to	⊕⊕⊕⊕ High	Important
All 14	Randomized trials	Not serious	Not serious	Not serious	Not serious	Publica- tion bias strongly suspected	156/775 (20.1%)	252/791 (31.9%)	<b>RR 0.63</b> (0.54 to 0.74)	116 fewer <b>118 fewer</b> <b>per 1000</b> (from 147 to 83 fewer)	⊕⊕⊕() moderate	Important

Bold values indicate Relative risk (RR)



Fig. 5 Funnel plot of included randomized controlled trials demonstrating the treatment effect relative to study size. Solid black dots represent true effect values, and the hollow circles represent the virtual effect value filled by the trim-and-fill method

p < 0.001; incision infection: RR = 0.60, 95% CI 0.44-0.81, p < 0.01; central line infection: RR = 0.51, 95% CI 0.27-0.96, p = 0.04; pneumonia infection: RR = 0.52, 95% CI 0.29–0.95, p = 0.03; urinary infection: RR = 0.35, 95% CI 0.19–0.67, p < 0.001; incidence of diarrhea: RR = 0.52, 95% CI 0.38–0.70, p < 0.001). Only low heterogeneity was detected in the meta-analysis for the central line infection  $(I^2 = 39\%;$  Fig. 4C). Furthermore, the GRADEpro was applied to rate the quality of evidence (Table 2). Risk of bias, inconsistency, and imprecision of the interval estimation are the main uncertainties of the evidence. High certainty can be drawn that probiotics/synbiotics could reduce the incidence of diarrhea. Moderate certainty could be expected that probiotics/synbiotics were beneficial to protect colorectal cancer patients from developing septicemia, incision infection, pneumonia infection, and urinary infection. The correlation between probiotics/synbiotics and central line infection has low certainty. Additional studies are needed to confirm the findings due to low quality of evidence.

#### **Publication bias**

A funnel plot was used to visually assess for publication bias (Fig. 5). There was some asymmetry on the funnel plot, suggesting that studies are more likely to be published if positive outcomes are demonstrated. Egger's test also indicates that there exists publication bias (p < 0.001). The trimand-fill method was used to test whether this publication bias would affect the results of the comprehensive effect size [32], and the hollow circles represent the effect size of the fill. After automatic completion by the algorithm, a new comprehensive RR was obtained (RR = 0.72, 95% CI 0.62–0.84, p < 0.001), and its significance was unchanged from that before the trim-and-fill method. Therefore, to some extent, it can be shown that the result is not affected by publication bias.

#### **Risk of bias analysis**

The risk of bias of the studies included is summarized in Fig. 6. The Cochrane risk of bias tool was used to evaluate the selection bias, performance bias, detection bias, attrition bias, and other bias.

### Discussion

Postoperative infections were significantly correlated to recurrence and poor survival in CRC patients. To gain a better surgical outcome and long-term oncological outcome, postoperative infection should be minimized as much as possible [34]. Many RCTs have demonstrated that preoperative or postoperative administration of probiotics/synbiotics is beneficial to prevent postoperative infection [13–25]. In the present study, we evaluated the effect of perioperative or postoperative probiotics/synbiotics on postoperative infections in adult patients undergoing colorectal resections systematically.

In summary, the probiotics or synbiotics can prevent developing postoperative infectious complications as compared to the control group who received placebo or standard care (RR = 0.63, 95% CI 0.54–0.74, p < 0.001; Fig. 2). The subgroup difference between probiotics and synbiotics was not significant (p=0.54), and the subgroup difference between preoperative and postoperative administrations of probiotics/synbiotics was also not significant (p = 0.09). Furthermore, when considering the six types of postoperative infectious complications (septicemia, incision infection, central line infection, pneumonia infection, urinary infection, and incidence of diarrhea), probiotic or synbiotic administration significantly reduced the incidence of each of them, but more studies need to be carried out to confirm this conclusion due to the low quality of evidence. However, for the main outcome of infectious complications, we found evidence of possible publication bias, although estimates still showed a reduction following trim-and-fill analysis (RR = 0.72, 95% CI 0.62–0.84, *p* < 0.001).

Although probiotic use has been greatly popularized among the general public, there are conflicting clinical results for many probiotic strains and formulations [35]. Theoretical risks have been described in case reports, clinical trial results and experimental models, include systemic infections, deleterious metabolic activities, excessive



Fig. 6 Risk of bias analysis for the studies included

immune stimulation in susceptible individuals, gene transfer, and gastrointestinal side effects [36, 37]. The included studies did not report the incidence of side effects and mortality after administration of probiotics or synbiotics. Therefore, probiotics and synbiotics should be used in consideration of their possible side effects, which need to be confirmed by more studies [38].

This study has some limitations. First, beneficial outcomes of probiotic/synbiotics are more likely to be published, but the publication bias would not affect the results demonstrated by the trim-and-fill method. Second, the composition of probiotics/synbiotics and antibiotics used in each study varied, and different probiotic strains or antibiotics may have different capacities to prevent postoperative infection [39]. Most of the studies employed a *Lactobacillus* probiotic, while a few studies incorporated a *Bifidobacteria* species along with some prebiotics. Third, definitions of infectious complications were not specified among these studies, and differences in the definition of postoperative infectious complications can affect estimation of effect size. Fourth, the timing and duration of administration were different among these studies, and this factor should be important for the outcomes.

# Conclusions

In summary, the pre- or postoperative use of probiotics and synbiotics can prevent the development of all types of postoperative infectious complications as compared to the control group. There was a large variety of proposed probiotics/synbiotics; therefore, the effect on postoperative complications may not be the same for all. Finally, the results of our meta-analysis must be interpreted with caution and more studies need to be carried out to confirm our conclusions due to the low quality of evidence of the trials included.

**Funding** This study was supported by the National Natural Science Foundation of China (81871317) and Military medical innovation project (18CXZ025).

#### Declarations

**Conflict of interest** We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

**Ethics Statement** The study protocol was consistent with the Declaration of Helsinki (as revised in 2013). The approval from ethics board was not required since our study was a meta study.

**Informed Consent statements** Individual consent for this meta analysis was waived.

# References

- Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 68:394–424
- Siegel RL et al (2017) Colorectal cancer statistics, 2017. CA: Cancer J Clin 67:177–193
- Song M, Chan AT, Sun J (2020) Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology 158:322–340
- Xu Z et al (2020) Update on risk factors of surgical site infection in colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 35:2147–2156
- 5. MacFie J (2004) Current status of bacterial translocation as a cause of surgical sepsis. Br Med Bull 71:1–11
- Bartolini I et al (2020) Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: focus on short and long-term outcomes. World J Gastroenterol 26:2498–2513
- 7. Wieërs G et al (2019) How probiotics affect the microbiota. Front Cell Infect Microbiol 9:454
- 8. Holscher HD (2017) Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut microbes 8:172–184
- 9. Markowiak P, Śliżewska K (2017) Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 9:1021
- Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC (2009) Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15:300–310
- Morrow LE, Kollef MH (2008) Kollef Probiotics in the intensive care unit: why controversies and confusion abound. Crit Care 12:160
- Walker WA (2008) Mechanisms of action of probiotics. Clin Infect Dis: Off Publ Infect Dis Soc Am 46(Suppl 2):S87-91 (discussion S144–51)
- Liu Z et al (2011) Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery—a double-blind study. Aliment Pharmacol Ther 33:50–63

- Mangell P et al (2012) Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocation in patients undergoing colon resection. Dig Dis Sci 57:1915–1924
- Zhang J et al (2012) Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci 343:199–205
- 16. Liu Z et al (2013) The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr 97:117–126
- Sadahiro S et al (2014) Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. Surgery 155:493–503
- Kotzampassi K et al (2015) A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg 39:2776–2783
- Liu Z et al (2015) Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and doubleblind randomized clinical trial. BMC Gastroenterol 15:34
- Consoli MLD et al (2016) Randomized clinical trial: impact of oral administration of saccharomyces boulardii on gene expression of intestinal cytokines in patients undergoing colon resection. JPEN J Parenter Enter Nutr 40:1114–1121
- Tan CK et al (2016) Pre-surgical administration of microbial cell preparation in colorectal cancer patients: a randomized controlled trial. World J Surg 40:1985–1992
- Horvat M, Krebs B, Potrč S, Ivanecz A, Kompan L (2010) Preoperative synbiotic bowel conditioning for elective colorectal surgery. Wien Klin Wochenschr 122:26–30
- Komatsu S et al (2016) Efficacy of perioperative synbiotics treatment for the prevention of surgical site infection after laparoscopic colorectal surgery: a randomized controlled trial. Surg Today 46:479–490
- Flesch AT, Tonial ST, Contu PDC, Damin DC (2017) Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial. Rev Colegio Bras Cir 44:567–573
- Polakowski CB, Kato M, Preti VB, Schieferdecker MEM, Ligocki Campos AC (2019) Impact of the preoperative use of synbiotics in colorectal cancer patients: a prospective, randomized, doubleblind, placebo-controlled study. Nutrition (Burbank Los Angeles County, Calif) 58:40–46
- Amitay EL, Carr PR, Gies A, Laetsch DC, Brenner H (2020) Probiotic/synbiotic treatment and postoperative complications in colorectal cancer patients: systematic review and meta-analysis of randomized controlled trials. Clin Transl Gastroenterol 11:e00268
- Wu X et al (2018) Efficacy of prophylactic probiotics in combination with antibiotics versus antibiotics alone for colorectal surgery: a meta-analysis of randomized controlled trials. J Surg Oncol 117:1394–1404
- Qumseya BJ (2021) Quality assessment for systematic reviews and meta-analyses of cohort studies. Gastrointest Endosc 93:486e1–494e1
- Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94
- 30. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

- Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 315:629–634
- Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in metaanalysis. Biometrics 56:455–463
- 33. Yang Y et al (2016) The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget 7:8432–8440
- 34. Chen G et al (2021) Relationship between postoperative complications and the prognosis of gastric carcinoma patients who underwent surgical resection: a systematic review and meta-analysis. Cancer Control : J Moffitt Cancer Center 28:10732748211011956–10732748211011956
- 35. Suez J, Zmora N, Segal E, Elinav E (2019) The pros, cons, and many unknowns of probiotics. Nat Med 25:716–729

- Doron S, Snydman DR (2015) Risk and safety of probiotics. Clin Infect Dis: Off Publ Infect Dis Soc Am 60(Suppl 2):S129–S134
- Zawistowska-Rojek A, Tyski S (2018) Are probiotic really safe for humans? Pol J Microbiol 67:251–258
- Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M (2014) A systematic review of the safety of probiotics. Expert Opin Drug Saf 13:227–239
- 39. Jäger R et al (2019) International society of sports nutrition position stand: probiotics. J Int Soc Sports Nutr 16:62

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.